Victoza

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

Liraglutide

Inapatikana kutoka:

Novo Nordisk Pharmaceuticals Pty Ltd

Darasa:

Medicine Registered

Taarifa za kipeperushi

 
Victoza
® 

Page 1 of 9 
Victoza_cmi6.docx

VICTOZA
®

_Liraglutide (rys) _
CONSUMER MEDICINE INFORMATION 

WHAT IS IN THIS LEAFLET 
WHAT VICTOZA
®
 IS USED FOR ........ 1

BEFORE YOU USE VICTOZA
®
 ........... 1

HOW TO USE VICTOZA
®
 ................. 2

WHILE YOU ARE USING VICTOZA
®
 .. 3

THINGS TO BE CAREFUL OF .............. 3

SIDE EFFECTS ................................. 3

AFTER USING VICTOZA
®
 ................. 4

PRODUCT DESCRIPTION ................. 4

FURTHER INFORMATION ................. 4

INSTRUCTIONS FOR USE ................. 5

This leaflet answers some common 
questions about Victoza
®
. It does not 
contain all the available information. 
It does not take the place of talking 
to your doctor, diabetes 
educator/nurse or pharmacist. 
All medicines have risks and 
benefits. Your doctor has weighed 
the risks of you using Victoza
®

against the benefits they expect it 
will have for you. 
IF YOU HAVE ANY CONCERNS ABOUT 
USING THIS MEDICINE, ASK YOUR 
DOCTOR OR PHARMACIST. 
KEEP THIS LEAFLET WITH THE MEDICINE.

You may need to read it again.

WHAT VICTOZA
®
 IS USED 
FOR 
Victoza
®
 contains the active 
ingredient liraglutide. Victoza
®
 is an 
injection that is used once a day. 
Victoza
®
 is used to treat type 2 
diabetes mellitus.  
Diabetes mellitus is a condition 
where your pancreas does not 
produce enough insulin to control 
your blood sugar (glucose) level.  
If you have type 2 diabetes mellitus 
your body is also not able to use 
insulin properly.  
Victoza
®
 helps your body to produce 
more insulin when your blood sugar 
level is high.  
Victoza
®
 is used when previous 
medicines have not been enough to 
control your blood sugar levels. Your 
doctor may want you to use one or 
more other medicines in addition to 
Victoza
®
, such as metformin or a 
sulfonylurea. It is also i

Tabia za bidhaa

Product Information 
Victoza_pi5a.docx 
Page 1 of 20

PRODUCT INFORMATION 

LIRAGLUTIDE

VICTOZA
®

NAME OF THE MEDICINE 
Liraglutide (rys) 

Liraglutide (rys) has the molecular formula C
172
H
265
N
43
O
51
 and a molecular weight of 3751.20 daltons. 

CAS No.: 204656-20-2 
DESCRIPTION

Liraglutide is a human Glucagon-Like Peptide-1 (GLP-1) analogue that
binds to and activates the GLP-
1 receptor. The GLP-1 receptor is the target for native GLP-1, an
endogenous incretin hormone that 
potentiates glucose-dependent insulin secretion
from the pancreatic beta cells. Liraglutide exhibits 97% 
homology to human GLP-1. In liraglutide, the lysine at position 34
has been replaced with arginine, and 
a palmitic acid has been attached via a glutamoyl spacer to lysine at
position 26. 

Liraglutide is produced by recombinant DNA technology
using _Saccharomyces cerevisiae_. One mL 
contains 6 mg salt-free anhydrous liraglutide. Victoza
®
 is a sterile, clear, colourless, isotonic solution of 
liraglutide 6 mg/mL (pH=8.15). Victoza is a solution for injection.

Each mL of Victoza also contains the following inactive
ingredients: 1.42 mg dibasic sodium phosphate 
dihydrate, 14.0 mg propylene
glycol, 5.5 mg phenol, hydrochloric acid q.s., sodium hydroxide
q.s. and 
water for injections to 1 mL. 
PHARMACOLOGY

_MECHANISM OF ACTION _
Unlike native GLP-1, liraglutide has a pharmacokinetic and
pharmacodynamic profile in humans 
suitable for once daily administration. Following subcutaneous
administration, the protracted action 
profile is based on three mechanisms: self-association (which
results in slow absorption), binding to 
albumin and enzymatic stability towards the dipeptidyl peptidase
(DPP-IV) and neutral endopeptidase 
(NEP) enzymes, resulting in a long plasma half life.  

Liraglutide action is mediated via a specific interaction with GLP-1
receptors, leading to an increase in 
cyclic adenosine monophosphate (cAM